We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00178646
Recruitment Status : Completed
First Posted : September 15, 2005
Last Update Posted : January 9, 2014
Information provided by (Responsible Party):
Gerard Francisco, The University of Texas Health Science Center, Houston

September 12, 2005
September 15, 2005
January 9, 2014
January 2002
March 2010   (Final data collection date for primary outcome measure)
Ashworth Scale [ Time Frame: 8 weeks ]
Ashworth Scale
Complete list of historical versions of study NCT00178646 on ClinicalTrials.gov Archive Site
Range of Motion [ Time Frame: 8 weeks ]
Range of Motion
Not Provided
Not Provided
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
Comparative Efficacy of Three Preparations of Botox-A in Treating Spasticity
The study seeks to compare the effectiveness of three preparations of BOTOX-A® in treating muscle tightness and spasms in the feet and ankles of people with stroke.

Spasticity is one of the most debilitating complications of neurologic conditions, such as stroke, brain injury, spinal cord injury, cerebral palsy, and multiple sclerosis. Although the exact pathophysiology is unknown, it is believed to result from an imbalance of ascending excitatory influences on and descending inhibitory components of the central nervous system. Clinically, spasticity manifests as abnormally increased muscle tone, associated with loss of range of motion, increased muscle stretch reflexes, clonus, weakness, and incoordination. If inadequately treated, spasticity leads to more disability and increase health care costs. Common complications of inadequately treated spasticity include joint and muscle contracture, pain, difficulty with performing activities of daily living and hygiene, and impaired transfers and ambulation.

Acquired brain injuries (ABI), including stroke, traumatic brain injury, and encephalopathy, often lead to long-term impairments, including spasticity. In severe cases, spasticity is difficult and frustrating to treat in this patient population, since the individuals may not tolerate the side effects of conventional therapies because of ABI-related deficits in arousal and cognition. Systemic medications, such as baclofen and tizanidine, are effective in controlling spasticity; however, they may also cause sleepiness and drowsiness, and impair memory and thinking processes---adverse effects that individuals with ABI may not tolerate.

Thus, "local" treatments, such as neurolysis and chemodenervation using botulinum toxin, have become superior treatment options in individuals with ABI, since they are devoid of the usual side effects of systemic medications. They are also effective in controlling spasticity, yet they do not impair arousal and cognition. The medical literature is replete with reports of the efficacy of botulinum toxin-A in the management of spasticity. Thus, the current challenge for clinicians and researchers at this time is to find ways to further enhance the efficacy of botulinum toxin. One way to achieve this is by exploiting certain properties of the toxin. Animal studies and clinical experience have shown that the effects of the drug is dose-dependent. One other property is the flexibility in preparing the volume of drug injected. Since botulinum toxin, as it is currently available (as BOTOX-A®) in the United States, requires reconstitution with preservative-free saline, there is flexibility for clinicians to manipulate the volume of solution that will be administered, without altering the dose.

We recently completed a trial comparing the effects of two volume preparations of BOTOX-A® on wrist and finger flexor spasticity of individuals with ABI. One group of patients received BOTOX-A® prepared as 100 units/cc, while another received BOTOX-A® prepared as 50 units/cc. Although there was no statistically significant difference between the two groups, there was a trend in favor of the group that received the higher volume, i.e.; they appeared to improve more based on decrease in muscle tone (measured by the Modified Ashworth Scale). This was compared by the clinician's global impression that the high volume group improved more. The latter measure achieved statistical significance. One possible reason for the absence of statistical significance was that the "high" volume (50 units/cc) was not high enough. Thus, we are proposing this study to investigate the comparative effects of three preparations of BOTOX-A®.

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single (Outcomes Assessor)
Primary Purpose: Treatment
  • Stroke
  • Brain Injuries
  • Spasticity
Drug: Botox
Botox 75-150 units, single treatment only
Other Name: generic name: botulinum toxin type A
  • Active Comparator: 1
    Botox, 150 units prepared as 100 units/ml
    Intervention: Drug: Botox
  • Active Comparator: 2
    Botox 150 units, prepared as 50 units/ml.
    Intervention: Drug: Botox
  • Active Comparator: 3
    Botox 75 units, prepared as 25 units/ml.
    Intervention: Drug: Botox
Francisco GE, Boake C, Vaughn A. Botulinum toxin in upper limb spasticity after acquired brain injury: a randomized trial comparing dilution techniques. Am J Phys Med Rehabil. 2002 May;81(5):355-63.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
March 2010
March 2010   (Final data collection date for primary outcome measure)

Inclusion Criteria -

  • Spasticity resulting from ABI (stroke, including vascular malformations, traumatic brain injury)
  • Ashworth Score (resting) of at least 2 of the primary ankle plantarflexor (gastrocnemius)
  • Onset of primary illness at least six months prior to study inclusion
  • At least 12 years of age

Exclusion Criteria -

  • Hypersensitivity or allergy to botulinum toxin
  • History of myasthenia gravis or other neuromuscular disease
  • Current use of aminoglycosides
  • Botulinum toxin or phenol injection to study limb within six months prior to recruitment
  • Current use of other spasmolytic drug, such as diazepam, baclofen, dantrolene, tizanidine
  • Presence of contracture or significant muscle atrophy
  • Pregnancy
Sexes Eligible for Study: All
12 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
United States
Not Provided
Not Provided
Gerard Francisco, The University of Texas Health Science Center, Houston
The University of Texas Health Science Center, Houston
Principal Investigator: Gerard E Francisco, MD University of Texas
The University of Texas Health Science Center, Houston
December 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP